Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology

Jia Xin Yu; Amanda J. Craig; Mary E. Duffy; Carlos Villacorta-Martin; Verónica Miguela; Marina Ruiz de Galarreta; Alexander P. Scopton; Lisa Silber; Andres Y. Maldonado; Alexander Rialdi; Ernesto Guccione; Amaia Lujambio; Augusto Villanueva; Arvin C. Dar

doi:10.1158/1535-7163.MCT-18-0571

Small Molecule Therapeutics

Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology

Jia Xin Yu, Amanda J. Craig, Mary E. Duffy, Carlos Villacorta-Martin, Verónica Miguela, Marina Ruiz de Galarreta, Alexander P. Scopton, Lisa Silber, Andres Y. Maldonado, Alexander Rialdi, Ernesto Guccione, Amaia Lujambio, Augusto Villanueva and Arvin C. Dar

Jia Xin Yu

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

2Department of Pharmacological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

3Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Amanda J. Craig

3Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, New York.

4Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mary E. Duffy

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

2Department of Pharmacological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

3Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Carlos Villacorta-Martin

4Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Verónica Miguela

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

4Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

5Precision Immunology Institute at Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marina Ruiz de Galarreta

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

4Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

5Precision Immunology Institute at Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Marina Ruiz de Galarreta

Alexander P. Scopton

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

2Department of Pharmacological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lisa Silber

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

2Department of Pharmacological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andres Y. Maldonado

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

2Department of Pharmacological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alexander Rialdi

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

3Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, New York.

4Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ernesto Guccione

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

3Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, New York.

4Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Amaia Lujambio

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

3Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, New York.

4Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

5Precision Immunology Institute at Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Amaia Lujambio
For correspondence: arvin.dar@mssm.edu augusto.villanueva@mssm.edu amaia.lujambio@mssm.edu

Augusto Villanueva

3Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, New York.

4Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

6Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: arvin.dar@mssm.edu augusto.villanueva@mssm.edu amaia.lujambio@mssm.edu

Arvin C. Dar

1Department of Oncological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

2Department of Pharmacological Sciences, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai, New York, New York.

3Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, New York.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: arvin.dar@mssm.edu augusto.villanueva@mssm.edu amaia.lujambio@mssm.edu

DOI: 10.1158/1535-7163.MCT-18-0571 Published September 2019

Article
Figures & Data
Info & Metrics
PDF

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

PreviousNext

September 2019
Volume 18, Issue 9

Table of Contents
Table of Contents (PDF)
About the Cover
Editorial Board (PDF)

Search for this keyword

View this article with LENS

Open full page PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology

Message Subject (Your Name) has forwarded a page to you from Molecular Cancer Therapeutics

Message Body (Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology

Mol Cancer Ther September 1 2019 (18) (9) 1506-1519; DOI: 10.1158/1535-7163.MCT-18-0571

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology

Mol Cancer Ther September 1 2019 (18) (9) 1506-1519; DOI: 10.1158/1535-7163.MCT-18-0571

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Main menu

User menu

Search

Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology

Purchase access

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Articles

Info for

About MCT